Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy

EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs

EP: 3.Payers Review Process and Effective Strategies for PDT Coverage

Now Viewing

EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

EP: 5.Dawn of the Age of Adopting PDTs

EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

EP: 7.Evolving Commercialization and Distribution Models for PDTs

EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support

EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access

EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Related Videos

Related Content

Advertisement

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

Related Content

Advertisement

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.